Stoke Therapeutics, Inc. (STOK)
STOKNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$27.71
+1.17 (+4.41%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $1.81bn
- P/E
- –
- EPS, last 4 quarters
- $-3.77
- Dividend yield
- –
- Day range
- –
- 52-week range
- $21.68 to $40.22
- Average volume
- 1.08m
- Previous close
- $26.54
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $48.75, +75.9% from here
Earnings
next estimate $-1.10Next report
Dec 2025
-29.3%
Mar 2026
+1.3%
Jun 2026
-13.4%
Sep 2026
-22.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $1.40m | $6.23m | $9.32m | $11.25m |
| Gross profit | $1.40m | $6.23m | $9.32m | $11.25m |
| Operating income | -$61.44m | -$53.42m | -$65.43m | -$77.31m |
| Net income | -$57.93m | -$50.00m | -$61.62m | -$73.64m |
Last four quarters: revenue $28.21m, margin -862.1%, free cash flow -$215.72m
News
8 latest- Stoke (STOK) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 30, 2026
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesFintel · Oct 29, 2026
- Stoke Therapeutics Q3 Earnings Call HighlightsMarketBeat · Oct 29, 2026
- Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue EstimatesZacks · Oct 29, 2026
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals RTTNews · Sep 4, 2026
- Stoke And Biogen Unveil Long-Term Zorevunersen Data In Dravet Syndrome RTTNews · Sep 4, 2026
- Biogen: 4-year Data Support Potential Disease-modifying Effects Of Zorevunersen RTTNews · Sep 1, 2026
- Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero DropoutsMarketBeat · Aug 17, 2026
The company
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- stoketherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.